May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
February 3rd 2023
August 26th 2022
July 11th 2022
What Would CMS Proposed Coverage Decision for Next-Generation Sequencing Mean for Oncologists?February 16th 2018
The day when oncologists can order a Medicare-covered next-generation sequencing diagnostic test may be near at hand, but once this change goes into effect, will oncologists be limited to certain tests, labs, and cancer settings? The answer is unclear.
Clinical Urology Practices Should Include More Genomic Screening for Prostate CancerDecember 28th 2017
With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.
When to Order Next-Generation Sequencing for a Patient With Metastatic Colon CancerDecember 22nd 2017
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.
Breast Cancer Genome to Shape Precision MedicineSeptember 16th 2017
As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.
Expert Sees Molecular Genetics Increasingly Integrated into Clinical Decision Making in MPNsSeptember 16th 2017
Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.
ProfiLER Study Demonstrates Importance of Genomic Testing for Precision MedicineJune 4th 2017
Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine. Patients who received molecularly targeted agents based on genomic profiles had longer 3-year and 5-year overall survival than those who did not.